Roche FY24 Core Operating Profit Rises
Roche has given two early-phase bispecifics the heave-ho, ending work on a HER2xCD3 prospect and an IL-15 candidate it picked up from Xencor. | Roche has given two early-phase bispecifics the heave-ho ...
Roche’s freshly approved PI3K inhibitor Itovebi can help extend the lives of certain patients with breast cancer when used in ...
Gen.2 Molarity assay has received 510(k) clearance from the United States Food and Drug Administration (FDA). This will be the first 510(k) cleared test of its kind available in the U.S. measuring ...
EARNINGS FORECAST: Roche's core earnings per share are expected to come in at 18.59 francs, according to the Visible Alpha consensus. For 2023, the company reported core EPS of 18.57 francs. As of ...
Mumbai: Roche Pharma India has announced the appointment of Rajwinder (Rajji) Mehdwan as country General Manager, effective 1 ...
4d
Patients might not know about Roche Tissue Diagnostics, but the Arizona entity has been testing for cancer and helping devise ...
Effective February 10, 2025, Mamilli will assume global responsibility for the Informatics function for the Roche Group.
In this Made in Arizona, we're highlighting local artist Christopher Roach of Mesa. He uses art to showcase the beauty of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback